EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Characteristics and outcome of anti‐hepatitis D virus positive patients with hepatocellular carcinoma

Edoardo G Giannini iD, Andrea Pasta iD, Giulia Pieri iD, Maria Corina Plaz Torres iD, Mariarosaria Marseglia, Filippo Pelizzaro, Angelo Sangiovanni iD, Giuseppe Cabibbo iD, Giorgia Ghittoni, Mariella Di Marco, Francesco Giuseppe Foschi, Maria Guarino iD und 18 weitere

Liver International · 2024-07 · 44 (7) · 1588-1599

DOI: 10.1111/liv.15855 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, 2024-03. Verfasst von Edoardo G Giannini und 29 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology Unit, Department of Internal Medicine, University of Genoa, Genoa, Italy. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Hepatitis D, Chronic, Liver Transplantation. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background & Aims Chronic hepatitis D virus (HDV) often leads to end‐stage liver disease and hepatocellular carcinoma (HCC). Comprehensive data pertaining to large populations with HDV and HCC are missing, therefore we sought to assess the characteristics, management, and outcome of these patients, comparing them to patients with hepatitis B virus (HBV) infection.

Methods

We analysed the Italian Liver Cancer database focusing on patients with positivity for HBV surface antigen and anti‐HDV antibodies (HBV/HDV, n = 107) and patients with HBV infection alone ( n = 588). Clinical and oncological characteristics, treatment, and survival were compared in the two groups.

Results

Patients with HBV/HDV had worse liver function [Model for End‐stage Liver Disease score: 11 vs. 9, p < .0001; Child‐Turcotte‐Pugh score: 7 vs. 5, p < .0001] than patients with HBV. HCC was more frequently diagnosed during surveillance (72.9% vs. 52.4%, p = .0002), and the oncological stage was more frequently Milan‐in (67.3% vs. 52.7%, p = .005) in patients with HBV/HDV. Liver transplantation was more frequently performed in HBV/HDV than in HBV patients (36.4% vs. 9.5%), while the opposite was observed for resection (8.4% vs. 20.1%, p < .0001), and in a competing risk analysis, HBV/HDV patients had a higher probability of receiving transplantation, independently of liver function and oncological stage. A trend towards longer survival was observed in patients with HBV/HDV (50.4 vs. 44.4 months, p = .106).

Conclusions

In patients with HBV/HDV, HCC is diagnosed more frequently during surveillance, resulting in a less advanced cancer stage in patients with more deranged liver function than HBV alone. Patients with HBV/HDV have a heightened benefit from liver transplantation, positively influencing survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHepatitis D, ChronicLiver TransplantationHumansMaleFemaleMiddle AgedItalyAgedHepatitis Delta VirusHepatitis B Surface AntigensRetrospective StudiesHepatitis AntibodiesHepatitis B, ChronicAdult

Stichwörter der Autor:innen

liver transplantationoutcomesurvivaltreatment

Substanzen

Hepatitis B Surface AntigensHepatitis Antibodies

Autor:innen und Institutionen

  • Gastroenterology Unit, Department of Internal Medicine, University of Genoa, Genoa, Italy.
  • IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
  • Division of Internal Medicine, Hepatobiliary Diseases and Immunoallergology, University of Bologna, Bologna, Italy.
  • IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Department of Surgery, Oncology and Gastroenterology, Gastroenterology Unit, University of Padua, Padua, Italy.
  • Division of Gastroenterology and Hepatology, Fondazione IRCCS Ca' Granda Ospedale maggiore Policlinico and C.R.C. "A.M. & A. Migliavacca Center for Liver Disease", Milan, Italy.

ORCID-Profile: Edoardo G Giannini, Andrea Pasta, Giulia Pieri, Maria Corina Plaz Torres, Angelo Sangiovanni, Giuseppe Cabibbo, Maria Guarino, Claudia Campani, Antonio Gasbarrini, Maurizia Rossana Brunetto, Gerardo Nardone, Gianpaolo Vidili, Alessandro Vitale, Franco Trevisani

Zitieren

APA

Giannini, E. G., Pasta, A., Pieri, G., Plaz Torres, M. C., Marseglia, M., Pelizzaro, F., Sangiovanni, A., Cabibbo, G., Ghittoni, G., Di Marco, M., Foschi, F. G., Guarino, M., Biasini, E., Saitta, C., Campani, C., Svegliati-Baroni, G., Gasbarrini, A., Brunetto, M. R., Magalotti, D., …, & Italian Liver Cancer (ITA.LI.CA) group (2024). Characteristics and outcome of anti‐hepatitis D virus positive patients with hepatocellular carcinoma. Liver International, 44(7), 1588-1599. https://doi.org/10.1111/liv.15855

Vancouver

Giannini EG, Pasta A, Pieri G, Plaz Torres MC, Marseglia M, Pelizzaro F, et al. Characteristics and outcome of anti‐hepatitis D virus positive patients with hepatocellular carcinoma. Liver International. 2024;44(7):1588-1599. doi:10.1111/liv.15855

BibTeX
@article{Giannini2024,
  author = {Giannini, Edoardo G and Pasta, Andrea and Pieri, Giulia and Plaz Torres, Maria Corina and Marseglia, Mariarosaria and Pelizzaro, Filippo and Sangiovanni, Angelo and Cabibbo, Giuseppe and Ghittoni, Giorgia and Di Marco, Mariella and Foschi, Francesco Giuseppe and Guarino, Maria and Biasini, Elisabetta and Saitta, Carlo and Campani, Claudia and Svegliati-Baroni, Gianluca and Gasbarrini, Antonio and Brunetto, Maurizia Rossana and Magalotti, Donatella and Azzaroli, Francesco and Mega, Andrea and Sacco, Rodolfo and Nardone, Gerardo and Sacerdoti, David and Masotto, Alberto and Vidili, Gianpaolo and Bucci, Laura and Vitale, Alessandro and Trevisani, Franco and Italian Liver Cancer (ITA.LI.CA) group, Italian Liver Cancer (ITA.LI.CA) group},
  title = {Characteristics and outcome of anti‐hepatitis D virus positive patients with hepatocellular carcinoma},
  journal = {Liver International},
  year = {2024},
  volume = {44},
  number = {7},
  pages = {1588--1599},
  doi = {10.1111/liv.15855}
}
Kostenlos starten →